https://doi.org/10.1192/bjp.175.4.391a Published online by Cambridge University Press

combinations of drugs and high-dose dual-action antidepressants.

We feel it necessary to point out that in our clinical experience therapeutic efficacy in resistant depression necessitates enhancement of noradrenergic neurotransmission. Drugs that increase noradrenergic neurotransmission have been shown to enhance drive, motivation and vigilance and it is clear that these are significantly impaired in those with severe depressive disorders and perhaps even more so in those with treatment-resistant depression (Weiss *et al*, 1995/1996).

Many of the 'older' antidepressants (tricyclics and monoamine oxidase inhibitors) are effective in treatment-resistant depression provided they are prescribed at sufficiently high doses; however, this incurs significant risks to the patient and is not a strategy that can be safely used on an outpatient basis because of the need to monitor antidepressant blood levels closely in order to avoid serious side-effects (Hodgkiss *et al*, 1995).

Venlafaxine displays differential effects according to dose. At low therapeutic doses it preferentially enhances serotonergic neurotransmission, whereas at higher doses it also enhances noradrenergic neurotransmission. Clinically, this is borne out to some extent by its pattern of side-effects; nausea and anxiety at low doses and an increase in blood pressure at high doses (Danjou & Hackett, 1995).

Danjou, P. & Hackett, D. (1995) Safety and tolerance profile of venlafaxine. *International Journal of Psychopharmacology*, **10** (suppl. 2), 15–20.

Hodgkiss, A. D., McCarthy, P. T., Sulke, A. N., *et al* (1995) High dose tertiary amine tricyclic antidepressants in the treatment of severe refractory depression. The central role of plasma concentration estimations. *Human Psychopharmacology*, **10**, 407–415.

Poirier, M.-F. & Boyer, P. (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. *British Journal of Psychiatry*, **175**, 12–16.

Weiss, J. M., Demetrikopoulo, K. & West, C. H. K. (1995/1996) Hypothesis linking the noradrenergic and dopaminergic systems in depression. *Depression*, **3**, 225–245.

G. S. Malhi, A. E. Farmer National Unit for Affective Disorders, Maudsley Hospital, Denmark Hill, London SE5 8AZ

Pharmacokinetics of clozapine

Author's reply: We appreciate Dr Swift's (1999) interest in our research (Kurz *et al*, 1998). The letter posed two questions: first, is there a relationship between plasma level variability and clinical deterioration? Second, what are the causes for plasma level variability?

The first question cannot be answered from our study, as we have only included patients into the drug-monitoring programme who were on clozapine for at least 25 weeks. Relapse among patients on medication was rarely seen and did not lead to withdrawal from clozapine (Kurz *et al*, 1996). Our sample, therefore, clearly consists of positively selected patients concerning their psychopathology. On the other hand, both the in- and the out-patient course of treatment was followed. There is a lack of long-term studies on pharmacokinetics in psychopathologically stable patients. In such patients, the variability of plasma levels was not followed by changes in psychopathology.

The causes for intra-individual variations in antipsychotic plasma levels are manifold and are discussed extensively in our paper. A lack of compliance concerning drug intake is a very important issue in this respect. However, even in studies with controlled drug intake or depot medication, moderate to high inter- and intra-individual variations in plasma levels have been found. It should be pointed out that in our sample no patient showed any plasma level below measurable values, and those patients who showed high intra-individual coefficients of variation usually had only one markedly aberrant plasma level during the investigation period. This means that all patients had adequate therapeutic levels most of the time. This suggests good compliance. We are convinced that one of the main causes for stability in these patients was the treatment setting of the drug-monitoring programme that provided a good therapeutic alliance with high motivational support.

We cannot definitively answer the question of whether regular assessment of plasma levels is useful in all patients on clozapine maintenance treatment. The crucial finding in our study is that patients will remain stable *despite* a fluctuation in plasma levels, and clinicians should not worry if single plasma level measurements are within a reasonably large range of variation.

Kurz, M., Hummer, M., Oberbauer, H., *et al* (1996) Termination of clozapine treatment. *Schizophrenia Research*, **18**, 125

—, —, Kemmler, G., *et al* (1998) Long-term pharmacokinetics of clozapine. *British Journal of Psychiatry*, **173**, 341–344.

Swift, G. (1999) Pharmacokinetics of clozapine (letter). *British Journal of Psychiatry*, **175**, 288.

M. Kurz University Clinics, Department of Biological Psychiatry, Anichstrasse 35, A-6020 Innsbruck, Austria

Olanzapine and tardive dyskinesia

Sir: A recent article reported that annual tardive dyskinesia (TD) risk is significantly lower for olanzapine (0.52%) than for haloperidol (7.45%) (Beasley *et al*, 1999).

One alternative hypothesis that could account for the low reported risk for olanzapine is that the Abnormal Involuntary Movement Scale (AIMS) measurements as implemented could have been insensitive to detect true TD. AIMS training, interrater reliability, and quality monitoring procedures are not described. Assay of sensitivity for the AIMS assessments as implemented in this study to detect true TD may be available, in that TD prevalence as assessed by the AIMS at baseline could be compared with previous TD prevalence studies of patients with equivalent antipsychotic exposure. However, current TD prevalence determined on baseline AIMS examination is not reported (as distinct from historical but not current TD or from exclusion from incidence analysis because of not completing two assessments after baseline).

Alternative hypotheses for the high risk observed in the haloperidol group also are possible. Previous research on patients at similar risk because of similar 10–15 years of previous TD-free antipsychotic exposure suggests that the risk of new cases of TD on continued conventional antipsychotic is only 3% annually (Glazer *et al*, 1993). There are only five cases of TD in the haloperidol group – could some of these be false positives? The report indicates that some cases of withdrawal dyskinesia may still be contained in the data set, despite exclusion of the first six weeks of data. The Schooler–Kane criteria specified that persistent TD should not be diagnosed until 12 weeks after medication change (Schooler & Kane, 1982). Inspection of Fig. 1 suggests that some of the haloperidol cases occurred between week 6 and week 12. Analysis excluding this interval would be of interest. Another possible source of false positive TD cases could be pseudoparkinsonism or akathisia, which can be mistaken for TD (Munetz & Cornes, 1983; Cummings &